clinical trial · NCT05943522
Asciminib RMP Study
Chronic Myeloid LeukemiaAsciminib
brief summary
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
started
Jul 19, 2023
primary completion
Jun 7, 2030
completion
Jun 7, 2030
last updated
Apr 20, 2026
detailed description
The dosage and duration of treatment may be considered and decided by the investigator in accordance with prescribing information of Asciminib.
This study will enroll all patients by total enumeration for those prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice for 2 years after the market launch.
official title
A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol